gms | German Medical Science

24th Annual Meeting of the German Retina Society

German Retina Society

17.06. - 18.06.2011, Aachen

Efficacy of Ozurdex in retinal vein occlusion

Meeting Abstract

  • Sibylle Winterhalter - Universitäts-Augenklinik Charité, Berlin
  • D. Ottenberg - Universitäts-Augenklinik Charité, Berlin
  • M. de Ruijter - Universitäts-Augenklinik Charité, Berlin
  • V. Kakkassery - Universitäts-Augenklinik Charité, Berlin
  • A.M. Joussen - Universitäts-Augenklinik Charité, Berlin

German Retina Society. 24th Annual Conference of the German Retina Society. Aachen, 17.-18.06.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11rg45

doi: 10.3205/11rg45, urn:nbn:de:0183-11rg458

This is the translated version of the article.
The original version can be found at:

Published: June 15, 2011

© 2011 Winterhalter et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Purpose: First results of efficacy and side effects after Ozurdex implantation in retinal vein occlusion.

Methods: 38 patients with branch or central retinal vein occlusion were treated with Ozurdex implantation from November 2010 till March 2011. Visual acuity, IOP and SD-OCT were measured monthly.

Results: 38 patients with retinal vein occlusion were treated with Ozurdex. The occlusion happened 1 to 36 months before. 9 patients were pretreated with Avastin. Before Ozurdex implantation mean visual acuity was 0.23 (hand movement to 0.9), mean IOP was 15.9 mmHg and mean central retinal was 592.6 µm (292–1269 µm). At baseline 11 patients were treated with antiglaucomatous therapy. No patient suffered from post operative leakage. The one month control was performed in 23 patients in whom mean visual acuity was 0.29 (0.029–0.6) and mean IOP was 18.86 mmHg (11–40 mmHg). One IOP decomensation to 38 mmHg was seen after implantation in a PEX patient and two more to 38 and 40 mmHg were seen 4 and 8 weeks after implantation. Mean central retinal thickness was 321.63 µm (191–882 µm). Five patients reached the two months control with a mean visual acuity of 0.48 (0.2–0.7), a mean IOP of 19.16 mmHg (12–27 mmHg) and a mean central retinal thickness of 289.38 µm (249–349 µm).

Conclusions: The first results of Ozurdex showed a good efficacy in patients with retinal vein occlusions. Further monthly visits will reveal the time of efficacy, IOP development and visual prognosis.